MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.rpth.2026.103398

Медицинская библиотека · Research and practice in thrombosis and haemostasis · 2026

Safety and efficacy of rivaroxaban versus warfarin in atrial fibrillation with stage 4 to 5 chronic kidney disease including dialysis.

Almajdi Anwar, Almutairi Sara, Alharbi Maha

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

Patients with atrial fibrillation (AF) and advanced chronic kidney disease (CKD) face elevated risks of stroke and bleeding; yet, optimal anticoagulation remains uncertain due to their exclusion from randomized trials. This systematic review and meta-analysis evaluated rivaroxaban vs warfarin in patients with AF and moderate-to-advanced CKD including dialysis.

METHODS

We searched PubMed/MEDLINE, Embase, and Cochrane CENTRAL through August 2025 for observational studies comparing rivaroxaban with warfarin in adults with nonvalvular AF and CKD stages 4 to 5 including dialysis. Primary outcomes were stroke/systemic embolism and major bleeding. Pooled hazard ratios (HRs) were calculated using random-effects models. Risk of bias was assessed using ROBINS-I, and certainty of evidence was evaluated using GRADE.

RESULTS

Four observational studies encompassing 31,037 patients of whom 12,160 received rivaroxaban and 18,877 received warfarin. Mean age ranged from 66 to 80 years, with CHA2DS2-VASc scores ranging from 3.5 to 4.5. Reduced-dose rivaroxaban (10-15 mg daily) was commonly prescribed. Compared with warfarin, rivaroxaban demonstrated a 30% reduction in stroke/systemic embolism (pooled HR, 0.70; 95% CI, 0.54-0.92; P = .009; I 2 = 38.1%) and 17% reduction in major bleeding (HR, 0.83; 95% CI, 0.72-0.97; P = .018). Favorable but nonsignificant trends were observed for intracranial hemorrhage (HR, 0.73; 95% CI, 0.49-1.08) and gastrointestinal bleeding (HR, 0.68; 95% CI, 0.46-1.03). Overall evidence quality was moderate according to GRADE assessment.

CONCLUSION

In patients with AF and advanced CKD including dialysis, rivaroxaban may be associated with improved efficacy and safety compared with warfarin. However, heterogeneity in CKD stages and off-label dosing practices necessitate prospective randomized trials to establish definitive treatment recommendations.

Для цитирования: Almajdi Anwar, Almutairi Sara, Alharbi Maha. Safety and efficacy of rivaroxaban versus warfarin in atrial fibrillation with stage 4 to 5 chronic kidney disease including dialysis.. Research and practice in thrombosis and haemostasis. 2026. DOI: 10.1016/j.rpth.2026.103398.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.